"We are working specifically with the reactivity of disulphide bridges in proteins - and we have verified that we can open them with UV light, provided that they are flanked with an aromatic group, eg TRP. In the open reactive state they can react…"
"1.Strong interaction with thiol groups present in cell respiratory enzymes in the microbe cell.
2.Interaction with structural proteins and preferential binding with DNA bases to inhibit replication.
3.Binding of the silver ion to free sulphydryl…"
My research field or area of interest innanotechnology
Pancreatic Cancer, Skin Cancer, Nanomedicine
Anti-cancer and chemo-preventive activity of natural compounds,Identification and characterization of novel therapeutic targets against cancer,Development of novel nano-delivery system to target cancer cells,Nanotoxicology, silver nanoparticles
1.Bhardwaj, A., Singh. S., Srivastava, S.K., Arora, S., Hyde, S. J., Andrews, J., Grizzle, W.E., Singh, A.P. (2014). Restoration of PPP2CA expression reverses epithelial to mesenchymal transition and suppresses prostate tumor growth and metastasis in an orthotopic mouse model. British Journal of Cancer. 110, 2000-2010.
2. Arora, S., Bhardwaj, A., Singh, S., Srivastava, S.K., McClellan S., Nirodi C.S., Piazza, G.A., Grizzle W.E., Owen, L, B., & Singh, A.P., (2013). An undesired effect of chemotherapy: gemcitabine promotes pancreatic cancer cell invasiveness through ROS-dependent, NF-κB- and HIF-1α-mediated upregulation of CXCR4. Journal of Biological chemistry. 288(29):21197-207.
3. Bhardwaj, A., Arora, S., Prajapati, V.K., Singh, S., and Singh, A.P. (2013). Cancer “Stemness”-Regulating miRNAs: Role, Mechanisms and Therapeutic Potential. Current Drug Targets.14 (10):1175-84.
4. Singh, A.P., Arora,S., Bhardwaj, A., Srivastava, S.K., Kadakia, M.P., Wang, B., Grizzle W.E., Owen, L,B., and Singh, S (2012). CXCL12/CXCR4 signaling axis induces SHH expression in pancreatic cancer cells via ERK- and Akt- mediated activation of NF-κB: implications for bidirectional tumor-stromal interactions. Journal of Biological chemistry. 287(46):39115-24.
5. Arora, S., Singh, S., Piazza, G.A., Contreas, C.M., Panyam, J., and Singh, A.P. (2012). Honokiol: a novel natural agent for cancer prevention and therapy. Current Molecular Medicine. 12 (10); 1244-1252.
6. Srivastava S.K., Bhardwaj A., Singh S., Arora S., McClellan S., Grizzle W.E., Reed E., and Singh A.P. (2012). Myb overexpression overrides androgen depletion- induced cell cycle arrest and apoptosis in prostate cancer cells, and confers aggressive malignant traits: potential role in castration-resistance. Carcinogenesis. 33(6):1149-1157.
7. Arora, S., Bhardwaj, A., Srivastava, S., Singh, S., McClellan, S., Wang, B & Singh, A.P. (2011). Honokiol arrests cell cycle, induces apoptosis, and potentiates the cytotoxic effect of gemcitabine in human pancreatic cancer cells. PLoS ONE. 6 (6): e21573.
8. Srivastava S., Bhardwaj A., Singh S., Arora S., Wang B., Grizzle W.E., and Singh A.P. (2011). MicroRNA-150 directly targets MUC4 and suppresses growth and malignant behavior of pancreatic cancer cells. Carcinogenesis. 32(12):1832-1839.
9. Malhi S.S., Budhiraja A., Arora S., Chaudhari K.R., Nepali K., Kumar R., Sohi H., and Murthy R.S. (2012). Intracellular delivery of redox cycler-doxorubicin to the mitochondria of cancer cell by folate receptor targeted mitocancerotropic liposomes. International Journal of Pharmaceutics. 432(1-2):63-74.
10. Arora, S., Rajwade, J.M., Paknikar, K.M., (2012). Nanotoxicology and in vitro studies: the need of the hour. Toxicology and applied pharmacology. 258:151-165.
11. Jain, J., Arora, S., Rajwade J.M., Omray, P., Khandelwal, S., Paknikar K.M., (2009). Silver Nanoparticles in Therapeutics: Development of an Antimicrobial Gel Formulation for Topical Use. Molecular Pharmaceutics, 6 (5), 1388–1401.
12. Arora, S., Jain, J.,Rajwade, J.M., Paknikar, K.M., (2009). Interactions of silver nanoparticles with primary mouse fibroblast and liver cells. Toxicology and applied pharmacology, 236, 310-318.
15. Kale, S.N., Rajagopal, R., Arora, S., Bhayani, K.R., Rajwade, J.M., Paknikar K.M., kundaliya, D.C., Ogale, S.B., (2007) Microwave response of La0.7Sr0.3MnO3 nanoparticles for heating applications. Journal of Biomedical Nanotechnology. 3, 178-183.
16. Bhayani, K.R., Kale, S.N., Arora, S., Rajagopal, R., Mamgain, H., Kaul-Ghanekar, R., Kundaliya, D.C., Kulkarni, S.D., pasricha, R., Dhole, S.D., Ogale, S.B., Paknikar, K.M., (2007). Protein and polymer immobilized La0.7Sr0.3MnO3 nanoparticles for possible biomedical applications. Nanotechnology.18, 1-7.
17. Kale, S.N., Arora, S., Bhayani, K.R., Paknikar, K.M., Rajagopal, R., Jani, M., Wagh, U.V., Kulkarni, S.D., Ogale, S.B., (2006). Cerium doping and stoichiometry control for biomedical use of La0.7Sr0.3MnO3 nanoparticles: microwave absorption and cytotoxicity study. Nanomedicine: Nanotechnology, biology and Medicine. 2, 217-221.
Researchgroup, Institute, University, School, Company name
USAMCI, Mobile NIPER, Mohali, ISF Moga, ARI Pune
Researchgroup, Institute, Company, University, School webpage
We are working specifically with the reactivity of disulphide bridges in proteins - and we have verified that we can open them with UV light, provided that they are flanked with an aromatic group, eg TRP. In the open reactive state they can react with gold surfaces, or gold nano particles.
As of yet we have not tried Silver, or Aluminum, but we expect Silver to be working well.
It could be interesting to mount antimicrobial peptides onto Silver nanoparticles, and check if their antimicrobial efficiency goes up or not
If you are interested in knowing mor please check our WEB pages for more info :
Welcome! Nanopaprika was cooked up by Hungarian chemistry PhD student in 2007. The main idea was to create something more personal than the other nano networks already on the Internet. Community is open to everyone from post-doctorial researchers and professors to students everywhere.
There is only one important assumption: you have to be interested in nano!
Nanopaprika is always looking for new partners, if you have any idea, contact me at firstname.lastname@example.org